A Study of rTMS for Cognitive Deficits in Chronic Patients With Schizophrenia

Not Applicable

Completed

• Conditions: Schizophrenia

• Registration Number: NCT03273439
• Lead Sponsor: Suzhou Psychiatric Hospital

Brief Summary

In this study, we assessed the therapeutic effects and safety of left dorsolateral prefrontal cortex (DLPFC) high-frequency repetitive transcranial magnetic stimulation (rTMS) on negative symptoms of schizophrenia. We evaluated the efficacy of rTMS on cognition in patients with chronic schizophrenia.

Detailed Description

This is a randomized, sham-controlled, double-blinded trial. 47 patients diagnosed with schizophrenia on stable antipsychotic treatment were randomly assigned to active rTMS treatment group (n=25) or a sham rTMS treatment group (n=22). 25 patients in the active rTMS group received 10 Hz 110% rTMS, while 22 patients were subjected to sham rTMS, both being given 4-week treatment (5 days per week). Efficacy of negative symptom was assessed with the Scale for the Assessment of Negative Symptoms (SANS), the Positive and Negative symptom scale (PANSS) at baseline, the end of 4 weeks and 8 weeks. The cognitive function was assessed with CANTAB at baseline, the end of 4 weeks and 8 weeks .The side effects were assessed with Treatment Emergent Symptoms Scale at baseline and the end of 4 weeks.

Study Timeline

• Study Start: 2012-07-01
• Primary Completion: 2014-02-01
• Study Completion: 2015-06-30
• Study First Submitted: 2017-03-15
• Status Verified: 2017-09
• Study First Submitted QC: 2017-09-05
• Last Update Submitted: 2017-09-05
• Study First Posted: 2017-09-06
• Last Update Posted: 2017-09-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

1. Right-handed;
2. meeting the diagnosis of schizophrenia for at least 2 years;
3. had been on anti-psychotic medications for more than 12 weeks;
4. with unresolved negative symptoms (SANS>20).

Exclusion Criteria

1. with substance use disorders ;
2. with cerebral pathologies (e.g. seizure, aneurysm, stroke), intra-cranial metals, pacemakers, severe cardiovascular diseases;
3. receiving electroconvulsive therapy in the past 3 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Scale for the Assessment of Negative Symptoms (SANS)	4 weeks	clinical negative symptoms

Secondary Outcome Measures

Name	Time	Method
Positive and Negative symptom scale (PANSS)	4 weeks	Clinical symptoms
CANTAB	4 weeks	cognition